124808-82-8

Upstream product

• 1193-65-3 3-quinuclidinone hydrochloride 
• 2627-86-3 (S)-1-phenyl-ethylamine 
• 120570-06-1 N-((S)-1-phenylethyl)-3-quinuclidinimine 
• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 120570-06-1 N-((R)-1-phenylethyl)-3-quinuclidinimine 

Downstream Products

• 6530-09-2 (S)-1-azabicyclo[2.2.2]oct-3-ylamine dihydrochloride 
• 6530-09-2 (3R)-quinuclidin-3-amine dihydrochloride 
• 142999-61-9 (S)-N-(R)-1-Aza-bicyclo[2.2.2]oct-3-yl-3,3,3-trifluoro-2-methoxy-2-phenyl-propionamide 
• 142999-66-4 (1-chloromethyl)-(3R)-3-<(S)-(1-phenyl)ethylamino>quinuclidinium chloride 
• 142999-61-9 (S)-N-(S)-1-Aza-bicyclo[2.2.2]oct-3-yl-3,3,3-trifluoro-2-methoxy-2-phenyl-propionamide 

Relevant academic research and scientific papers

Improved preparation of (R) and (S)-3-aminoquinuclidine dihydrochloride

An improved procedure for the synthesis of either (R) or (S)-3-aminoquinuclidine was developed. Key intermediate imine 2 was made in a one pot process using lithium oxide as the base and molecular sieves.

Anxiolytic-R-n(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides

Compounds of general formula I STR1 wherein: X represents oxygen or sulphur; each of R1 and R3 independently represents hydrogen or a C1 -C4 alkyl group; Ar represents: a phenyl ring optionally substituted by one, two or three C1 -C4 alkoxy groups and/or by one or two halogen atoms; a phenyl ring of the general formula STR2 wherein R2 represents halogen, 4,5-benzo, C1 -C8 alkoxy, C1 -C4 alkylcarbonyl or Am, wherein Am represents amino, methylamino or dimethylamino, R4 represents C1 -C8 alkyl, n is 1 or 2; or a pyrimidinyl moiety of the general formula STR3 wherein R5 is C1 -C4 alkyl; and their N-oxides and pharmaceutically acceptable salts are useful as anxiolytic agents. A preferred compound is R-(+)-4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide.

Enantiomers of absolute configuration S of amide derivatives of 3-aminoquinuclidine, the process for preparing them and their application in therapy

Enantiomer of absolute configuration S of formula: STR1 where: X=O or S; and Ar denotes a: * phenyl ring substituted with one, two or three C1 -C4 alkoxy groups; * phenyl ring substituted at the 2-position with a OCH3 group and at the 5-position with a halogen atom or a lower alkylcarbonyl group; * phenyl ring substituted at the 2-position with OCH3, at the 4-position with NH2 or alkylcarbonyl-NH and at the 5-position with a halogen; * 3-fluoro-2-methoxyphenyl group; * 5-pyrimidinyl group substituted at the 2-position with NH2 and in the 4-position with alkoxy or phenyloxy. These compounds are useful as medicinal products having activity in respect of gastric movements and antiemetic activity.

Method of treating or preventing schizophrenia and/or psychosis using S-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides

Compounds of general formula I STR1 wherein: X represents oxygen or sulphur; each of R1 and R3 independently represents hydrogen or a C1 -C4 alkyl group; Ar represents: a phenyl ring optionally substituted by one, two or three C1 -C4 alkoxy groups and/or by one or two halogen atoms; a phenyl ring of the general formula STR2 wherein R2 represents halogen, 4,5-benzo, C1 -C8 alkoxy, C1 -C4 alkylcarbonyl or Am, wherein Am represents amino, methylamino or dimethylamino, R4 represents C1 -C8 alkyl, n is 1 or 2; or a pyrimidinyl moiety of the general formula STR3 wherein R5 is C1 -C4 alkyl; and their N-oxides and pharmaceutically acceptable salts are useful as antischizophrenic and/or antipsychotic agents. A preferred compound is S(-)-4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide.